Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Latest filing published 12 Nov 2015 for NephroGenex, Inc..
Insider track record
Disclosed buys
0
Disclosed sells
6
Signal history
No signal scores available.
John Hamill: trading record in brief
This profile gathers the share dealings of John Hamill across 2 companies, led by Savient Pharmaceuticals Inc and NephroGenex, Inc. In total, 8 filings cover trades dated from 24 September 2012 to 10 November 2015.
Every open-market trade on record is a sale: 6 sales worth €2,173. Outside the open market, there are 2 share grants.
On 12 November 2015 came the latest disclosure, a share grant in NephroGenex, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to John Hamill
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
136,381 shares0Common StockSEC:0001559058-15-000005:0
1,500 shares@ US$0.079Common StockSEC:0001181431-13-054170:0
5,000 shares@ US$0.0791Common StockSEC:0001181431-13-054170:1
21,000 shares@ US$0.0795Common StockSEC:0001181431-13-054170:2
1,000 shares@ US$0.0796Common StockSEC:0001181431-13-054170:3
800 shares@ US$0.0798Common StockSEC:0001181431-13-054170:4
7,646 shares@ US$0.08Common StockSEC:0001181431-13-054170:5
100,000 shares@ US$2.92Common Stock, $0.01 par valueSEC:0001181431-12-052109:0
8 of 8 declarations
